Target intelligence / Profile preview

Angel homolog 1 (ANGEL1)

Target
ANGEL1
Molecular classification
Enzyme (member of the CCR4 deadenylase family), RNA-binding protein (eIF4E-binding activity)
01

Overview

Angel homolog 1 (ANGEL1) is a member of the CCR4 deadenylase family and serves as a modulator of post-transcriptional gene regulation, with specialized binding activity to eukaryotic initiation factor 4E (eIF4E). ANGEL1 is localized in various cellular compartments such as the endoplasmic reticulum, cis-Golgi network, perinuclear region, and mitochondrial outer membrane. It plays a role in selective mRNA stability regulation rather than general protein synthesis. Experimental evidence indicates that peptides derived from its eIF4E-binding motif can induce necrotic cell death specifically in epithelial cancer cell lines, positioning ANGEL1 as a candidate for targeted anti-cancer strategies. The gene is also associated with familial arrhythmogenic right ventricular dysplasia, but its primary molecular role centers on mRNA metabolism. ANGEL1 is evolutionarily conserved and grouped with other deadenylases such as PARN and Nocturnin, and its functions extend to fine-tuning gene expression at the post-transcriptional level.

Other names
CCR4EKIAA0759Protein angel homolog 1Ccr4eANGE1_HUMAN
02

Mechanism of action

Peptide derived from ANGEL1 induces rapid necrotic cell death, likely via inhibition or disruption of eIF4E interaction and post-transcriptional mRNA regulation. Broadly, modulation of deadenylase activity leading to altered mRNA stability.

03

Biological functions

Post-transcriptional regulation of gene expression (regulates select mRNA subsets via poly(A) tail dynamics)mRNA stability control (deadenylase activity)Protein domain-specific bindingInteraction with eukaryotic initiation factor 4E (eIF4E)
04

Disease associations

Cancer (synthetic peptides based on ANGEL1 binding motif induce cell death in cancer cells; implicated in oncology research)Arrhythmogenic right ventricular dysplasia, familial forms 8 and 9 (disease associations listed)Other (potentially implicated in other diseases based on GWAS and expression profiling, but cancer is primary)
05

Safety considerations

No notable safety concerns or therapeutic challenges are reported for ANGEL1-targeting therapies, as the field is predominantly preclinical.The induction of rapid cell death may indicate a need for caution regarding cytotoxicity and specificity in future drug development.
06

Interacting drugs

No approved drugs directly targeting ANGEL1 were found in the current search results.

1 more in the full profile.

07

Biomarkers

No clinically validated biomarkers were identified for ANGEL1 patient selection or efficacy monitoring.Experimental evidence of expression profiling in cancer and other tissues exists.

Beyond the preview

Go deeper on Angel homolog 1 (ANGEL1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Angel homolog 1 (ANGEL1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call